Germline knockout studies in female mice demonstrated an essential role for forkhead box L2 (FOXL2) in early follicle development, whereas an inducible granulosa cell (GC)-specific deletion of Foxl2 in adults has shown ovary-to-testis somatic sex reprogramming. In women, over 120 different germline mutations in the FOXL2 gene have been shown to cause blepharophimosis/ptosis/epicantus inversus syndrome associated with or without primary ovarian insufficiency. By contrast, a single somatic mutation (FOXL2
Germline knockout studies in female mice demonstrated an essential role for forkhead box L2 (FOXL2) in early follicle development, whereas an inducible granulosa cell (GC)-specific deletion of Foxl2 in adults has shown ovary-to-testis somatic sex reprogramming. In women, over 120 different germline mutations in the FOXL2 gene have been shown to cause blepharophimosis/ptosis/epicantus inversus syndrome associated with or without primary ovarian insufficiency. By contrast, a single somatic mutation (FOXL2
C134W
) accounts for almost all adult-type GC tumors (aGCTs). To test the hypothesis that FOXL2
C134W differentially regulates the expression of aGCT markers, we investigated the effect of FOXL2 C134W on inhibin B and P450 aromatase expression using a recently established human GC line (HGrC1), which we now show to bear two normal alleles of FOXL2. Neither FOXL2 wt nor FOXL2 C134W regulate INHBB messenger RNA (mRNA) expression. However, FOXL2 C134W selectively displays a 50-fold induction of CYP19 mRNA expression dependent upon activin A. Mechanistically, the CYP19 promoter is activated in a similar way by FOXL2 C134W interaction with SMAD3, but not by T he forkhead box L2 (FOXL2) is an evolutionarily conserved member of the forkhead transcription factor family (1) . Histological studies in humans, mice, and goats have detected FOXL2 messenger RNA (mRNA) and protein in the mesenchyme of developing eyelids, fetal and adult granulosa cells (GCs) of the ovary, embryonic as well as adult pituitary gonadotrope and thyrotroph cells of the pituitary, and endometrium of the uterus (1) (2) (3) (4) (5) (6) (7) (8) . Two Foxl2 germline null mouse models generated in different laboratories demonstrated high perinatal mortality (50% to 95%), most likely associated with coincident craniofacial defects (7, 9) . However, the surviving mice confirmed a critical role of FOXL2 in ovarian function, with a block in follicle development at the primary stage associated with a failure of GCs to complete the squamous-to-cuboidal transition. In contrast, the inducible somatic deletion of Foxl2 in GCs of adult mouse ovarian follicles led to the ovary-to-testis somatic sex reprogramming associated with the transdifferentiation of mature granulosa/theca cells into Sertoli/ Leydig-like cells as well as the upregulation of genes involved in testis determination vs the downregulation of ovary-specific genes, such as P450 aromatase (CYP19) (10) . Thus, FOXL2 appeared to be essential for the maintenance of the female gonadal sex throughout mouse life.
In humans, mutations in the FOXL2 gene are involved in diverse ovarian dysfunctions. More than 120 germline mutations of FOXL2 have been related to blepharophimosis/ptosis/epicantus inversus syndrome (BPES) associated with or without primary ovarian insufficiency (BPES type I and type II, respectively) (2, 11) . BPES type I typically results from FOXL2 truncations predicted to result in loss of function, whereas type II BPES mutations are generally hypomorphic and do not result in ovarian dysfunction (12, 13) . In striking contrast, a single somatic mutation, FOXL2 C134W , which was not found in BPES, was detected in almost all adult-type GC tumors (aGCTs) (14) , as collected from more than 400 patients of various ethnicities (15) . Although accumulating evidence suggested that FOXL2 C134W is a strong driver candidate in the pathogenesis of aGCTs (11, (16) (17) (18) (19) (20) (21) , the molecular basis of FOXL2 C134W action in regulating GC tumorigenesis is largely unknown.
FOXL2 regulates the transcription of various genes involved in diverse cellular processes such as steroidogenesis (e.g., STAR and CYP19), steroid metabolism (PPARGC1A and NR5A2), metabolism of reactive oxygen species (MnSOD or SOD2), stress response (SIRT1), cell cycle (CCND2, CCNA2, and P16/INK4a), and DNA repair (GADD45A and ALKBH8) (6, (22) (23) (24) (25) (26) (27) . In particular, FOXL2 regulation of CYP19 has been known across a variety of vertebrate species, including human, rodent, goat, fish, chicken, and frog (27) . The specificity of action of FOXL2 on such a wide spectrum of cellular functions is likely governed by its interaction with cofactors. Steroid factor 1 (SF1) is a key factor in steroidogenesis, as it regulates CYP11, CYP17, CYP19, and STAR (28). FOXL2 prevents SF1 binding to the CYP17 promoter, leading to the suppression of SF1-induced CYP17 expression (29) . In contrast, FOXL2 associates with SF1 and together enhance CYP19 promoter activity.
Interestingly, it was postulated that this dual regulation could play a role in the balance of androgen and estrogen biosynthesis (27, 29) . The DEAD-box protein DP103 is a regulator of SF1 (30) , which interacts with FOXL2 to induce apoptosis in Chinese hamster ovary (CHO) cells and rat primary GCs (31, 32) . Whether an abnormal FOXL2-DP103 interaction may explain FOXL2 C134W -mediated reduction in apoptotic potential is unknown (33, 34) . FOXL2 also interacts with estrogen receptor a (35) and inhibits the activation of the PTGS2 promoter by estrogen receptor a (10, 35) . Another partner of FOXL2 is SMAD3, which interacts with it to regulate GnRHR promoter in the pituitary (36) . Also within the pituitary, FOXL2 interacts with SMAD3 to stimulate FSHB and FST promoter activities (37) (38) (39) , and a similar interaction in regulating FST transcription was later confirmed in GCs (40, 41 ). An emerging and important molecular basis underlying the pathogenesis of GC tumors (GCTs) is an alteration in the SMAD3/ FOXL2 interaction (42) .
Many studies that investigate the role of FOXL2
in GCs use immortalized human GC lines, either KGN (16, 24, (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) or COV434 cells (16, 40, 46, 48, 49, 52, 53, 56) . The KGN cell line is derived from a postmenopausal woman with an aGCT (57) , whereas the COV434 cell line is from a 27-year-old woman (58) considered to have a juvenile GCT. In the current study, we used the HGrC1 cell line recently established by lentiviral-mediated transfer of immortalizing genes into human primary GCs derived from a normal right ovary of a 35-year-old woman (59 
Materials and Methods

Plasmids and reagents
Activin A was produced in our laboratory as previously described (60 (37) , and its mutant (FOXL2 C134W ) was constructed in our laboratory as previously described (40, 41) . Expression plasmids encoding human SMAD2 and SMAD3 with or without N-terminal Myc tags were prepared from those kindly provided by Drs. Kohei Miyazono (61, 62) and Louise Bilezikjian (37) . Luciferase reporter plasmids with different lengths of human CYP19 promoter were constructed in our laboratory using polymerase chain reaction (PCR)-based methods. Biotinylated oligonucleotide probes were purchased from Integrated DNA Technologies (San Diego, CA). 
HGrC1 cells culture
Transient transfections
HGrC1 cells were plated into either 12-well tissue culture plates at a density of 0.5 3 10 6 cells per well or 6-well tissue culture plates at a density of 1 3 10 6 cells/well. The next day, the medium was replaced with serum-free DMEM-F12 (supplemented with antibiotics), and transfection was performed with the previously described plasmids for 4 hours using Lipofectamine LTX with Plus Reagent (catalog no. 15338100; Thermo Fisher Scientific) following manufacturer's procedures. After 4 hours, medium was replaced with new serum-free DMEM-F12 and transfected cells were cultured at 37°C for 24 hours with or without activin A. Cells were then lysed for further analyses. 
RNA extractions and quantitative reverse transcription PCR
Western blot analysis
After 4-hour transfection and 24-hour culture at 37°C, HGrC1 cells were lysed in lysis buffer (radioimmunoprecipitation assay buffer; catalog no. 89901; Thermo Fisher Scientific), phosphatase inhibitor cocktail (catalog no. 78420; Thermo Fisher Scientific), and protease inhibitor cocktail (catalog no. P8340; Sigma-Aldrich), and total protein content was quantified with the Pierce BCA Protein Assay Kit (catalog no. 23227; Thermo Fisher Scientific). NuPAGE LDS Sample Buffer (4X) (catalog no. NP0007; Thermo Fisher Scientific) and b-mercaptoethanol (catalog no. 6010; Calbiochem, Billerica, MA) were added to cell lysates, and samples were heated to 95°C for 5 minutes for protein denaturation. Cell lysates were separated on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and then transferred to nitrocellulose membranes. The membranes were incubated for 1 hour with blocking solution (bovine serum albumin; catalog no. A30075-100; Research Products International, Mount Prospect, IL) and then with primary antibodies overnight at 4°C. Membranes were washed three times, incubated with horseradish peroxidase-conjugated secondary antibodies for 1 hour, washed three further times, and incubated with Super Signal West Femto Maximum Sensitivity Substrate for chemiluminescence detection (catalog no. 34095; Thermo Fisher Scientific). Alternatively, incubation of membranes in primary and secondary antibodies was performed in Signal Enhancer HIKARI solutions 1 and 2, respectively (nos. NU00101 and NU00102; Nacalai USA, San Diego, CA) to enhance protein detection. b-actin was used as a loading control.
Immunoassay
The E 2 Immunoassay Kit (catalog no. 582251; Caymen Chemical, Ann Arbor, MI) was used to measure estradiol (E 2 ) levels in culture media from HGrC1 cells transfected with either FOXL2 wt or FOXL2 C134W in the presence of androstenedione (100 nM), with or without activin A (100 ng/mL). After 4-hour transfection and 48-hour culture at 37°C, culture media from different treatments were collected in glass tubes and spun down to remove cell debris. E 2 was measured using a Bio Tek microplate reader (Bio Tek, Winooski, VT) following manufacturer's instructions. 
Luciferase reporter assay
Coimmunoprecipitation and oligonucleotide precipitation assays
After 4-hour transfection and 24-hour culture at 37°C, HGrC1 cells [2.5 3 10 6 cells/sample for coimmunoprecipitation (Co-IP) assay; 5 3 10 6 cells/sample for oligonucleotide precipitation assay] were lysed in lysis solution [25 mM tris (hydroxymethyl)aminomethane-HCl, pH 7.4, 140 mM NaCl, 1 mM EDTA, 0.1% NP-40, 0.5% Triton X-100, 10% glycerol, 2 mM NaF, and freshly added 1 mM Na 4 P 2 O 7 and protease inhibitor cocktail (catalog no. P8340; Sigma-Aldrich)]. Cell extracts were sonicated two times for 3 to 4 seconds each and centrifuged at 4°C for 10 minutes at 13,000 rpm, and supernatants were collected. For Co-IP assay, supernatants were precleared with mouse immunoglobulin G agarose (catalog no. A0919) for 1 hour, and then immunoprecipitations were performed with anti-FLAG M2 affinity gel (catalog no. A2220; Sigma-Aldrich) overnight at 4°C. The precipitants were washed three times in lysis buffer and eluted with FLAG peptide (catalog no. F3290; Sigma-Aldrich). Western blot analysis was performed to detect coprecipitating SMAD3 and FOXL2 proteins with anti-Myc and anti-Flag antibodies, respectively. For the oligonucleotide precipitation assay, 2 mg of biotinylated oligonucleotides were precoupled to streptavidin agarose (catalog no. 20353; Thermo Fisher Scientific) at 4°C for 1 hour and subsequently incubated with cell lysates together with 8 mg of poly(deoxyinosinic-deoxycytidylic) (catalog no. P4929; SigmaAldrich) at 4°C for 2 hours. Cell lysates were washed three times in lysis buffer and eluted with NuPage LDS Sample Buffer (catalog no. NP0007; Thermo Fisher Scientific). Immunoblot analysis was performed to detect FOXL2 proteins via the antiFlag antibody. Resolved band intensity was quantified using Image Laboratory Software from Bio-Rad (Hercules, CA).
Statistic analysis
Data analysis was performed with JMP Pro 12 software (Cary, NC) using Box-Cox transformation and one-way analysis of variance with least-squares means Tukey honest significant difference test or least-squares means Student t test. Significance was set at P , 0.05, and data are shown as mean 6 standard error of the mean (SEM).
Results
The coding sequence of the FOXL2 gene in HGrC1 cells is normal Prior to implementation of the HGrC1 cell line in this study, chromosome DNA extracted from HGrC1 cells was subjected to PCR to determine the DNA sequence of the FOXL2 gene. Although human FOXL2 gene is extremely rich in GC (.84% in some regions), we were able to determine the entire coding regions of the FOXL2 genes at both alleles, confirming they were intact and lacked mutation (data not shown).
FOXL2
C134W , but not FOXL2 wt , is a remarkable inducer of CYP19 mRNA expression in HGrC1 cells when treated with activin A HGrC1 cells were transfected with either FOXL2 wt or FOXL2 C134W plasmid, or their empty vector as a control. Cell lysates were collected and total protein content was measured to use equal amounts of proteins for sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. The inset in Fig. 1(a) shows the relative expression levels of endogenous FOXL2, exogenous FOXL2 wt and FOXL2 C134W (top panel), and b-actin (bottom panel).
Both FOXL2 wt and FOXL2 C134W proteins were expressed at comparable levels with elevated levels (.12-fold) relative to endogenous FOXL2 (which is almost invisible in this blot, but clearly detectable at longer exposures; data not shown). Cells were transfected and treated with or without activin A (100 ng/mL) for 24 hours to evaluate CYP19 and INHBB mRNA expression. Total RNA was then collected, and expression was analyzed by qRT-PCR [ Fig. 1(a The inset in Fig. 2(a) shows the endogenous and ectopically expressed (on average, 2.3-fold) levels of SMAD3 protein.
We noted that the overexpressed SMAD3 levels are comparable to endogenous SMAD2 levels, emphasizing the high level of endogenous expression of SMAD2 in HGrC1 cells [insets in Fig. 2(a) and Fig. 3 ]. FOXL2 wt did not influence CYP19 mRNA expression [ Fig. 2(a) ].
As previously observed, FOXL2 C134W (without SMAD3)
slightly but significantly induced CYP19 mRNA expression. However, when SMAD3 was ectopically expressed, FOXL2 C134W coexpressing cells increased CYP19 mRNA expression by eightfold compared with the control (P , 0.05), whereas coexpression with FOXL2 wt had no effect on CYP19 levels. In Fig. 2 plasmids and their empty vectors. The inset in Fig. 3 shows the endogenous and overexpressed (on average, 1.7-fold) levels of SMAD2 protein. Endogenous SMAD2 is higher than SMAD3 in HGrC1 cells [insets in Fig. 2(a) and Fig. 3 ]. Nonetheless, no difference in CYP19 mRNA levels between FOXL2 wt or FOXL2 C134W treatments (Fig. 3, lanes 2 and 3) was observed. Further, elevating the expression of SMAD2 did not alter these results (Fig. 3, lanes 5 and 6) . These data identify SMAD3 as selectively exerting a synergistic effect with FOXL2 C134W on the stimulation of CYP19 mRNA expression in HGrC1 cells. promoter activity. These data suggest that the induction of CYP19 mRNA expression by FOXL2 C134W and SMAD3 observed in HGrC1 cells occurs at the transcriptional level.
FBE5 is required to stimulate CYP19 transcription by FOXL2
C134W and SMAD3 To analyze which sites were necessary for the enhanced transcriptional activity observed, we next constructed a series of truncated luciferase reporters from the -823/ CYP19-Luc and evaluated their activities in HGrC1 cells expressing SMAD3, FOXL2 wt , and FOXL2 C134W alone or in combination (Fig. 6 ). is shown in the right panel of Fig. 6(a) C134W directly binds to the FBE5 in the proximal promoter of CYP19, we performed oligonucleotide precipitation assays with probes that include intact or mutated FBE5 and SBE sites [ Fig. 8(a) ]. Cells expressing combinations of SMAD3, FOXL2
wt , and FOXL2 C134W plasmids were treated with activin A for 24 hours, lysed, and subjected to precipitation 
Discussion
To study the molecular mechanisms underlying human GC function, GCs from in vitro fertilization patients have been widely used. However, there are substantial limitations in using in vitro fertilization GCs due to limited number of pooled GCs from several follicles that may have different gene expression profiles. Also, they are fully luteinized and do not survive in culture for an extended period. Reliable immortalized GCs are necessary as reproducible models of GC function. In the current study, experiments were carried out using a newly established, nonluteinized human GC cell line, HGrC1 (59). This cell line was established from GCs of the normal right ovary from a patient with monolateral mucinous adenocarcinoma at the left ovary and exhibits features of normal GCs at the early antral follicle stage expressing P450 aromatase and other GC-specific markers (59, 64) . Thus, the HGrC1 cell line is distinct from other GCT-derived cell lines such as KGN and COV434 and may be more suitable to use in studies to extrapolate data obtained with the rodent to the human model. In fact, KGN cells are heterozygous for FOXL2 C134W , whereas COV434 cells have a defect in FOXL2 gene transcription (52) . In contrast, our current study found that HGrC1 cells are homozygous for FOXL2 wt . Using HGrC1 cells, we present data that FOXL2 wt has no effect on CYP19 mRNA expression regardless of activin A treatment or SMAD3 overexpression. However, FOXL2 is known to repress many genes regulated by follicle-stimulating hormone, including CYP19, in CHO, KGN, and mouse primary GCs (65) (66) (67) . FOXL2 downregulates CYP19 expression in CHO cells (65) but upregulates CYP19 expression in COS7 cells and ovine primary GCs (68) as well as in Japanese flounder (69) and tilapia (70) . Therefore, FOXL2 regulation of CYP19 expression is controversial; the activity depends on the different cell types and species used in the study. Our key finding is that FOXL2
C134W
, but not FOXL2 wt , is able to induce CYP19 mRNA expression by an impressive 50-fold in the presence, but not absence, of activin A. Importantly, this was a functional change, as it corresponded to a 20-fold enhancement in estrogen level. This provides one mechanism to explain the increased levels of estrogen in women with aGCT. We further noted an eightfold increase in CYP19 when combined with SMAD3 expression. In fact, the eightfold increase would be remarkable if it were not overshadowed by the effect of FOXL2 C134W with activin A. This is a transcriptionally regulated process, because CYP19 promoter activity was also stimulated in a similar way. These data are in line with previously reported results by Fleming et al. (16) protein in the oligonucleotide coprecipitation assays despite our numerous attempts, including not only variations of experimental conditions, but also use of multiple inhibitors of alkaline phosphatase and a SMAD3 tagged with six copies of Myc to amplify our sensitivity relative to SMAD3 with one Myc epitope. The difference between biological and biochemical outcomes could be attributed to the difference in their experimental sensibilities. Thus, the precise mechanism by which SMAD3 is involved in the mechanism of FOXL2 C134W -induced CYP19 expression is not fully elucidated. However, our current data led us to propose a possible mechanism by which FOXL2 C134W and FOXL2 wt differently regulate CYP19 transcription with SMAD3 in HGrC1 cells as depicted in Fig. 9 . Our data and proposed mechanism support the model described by Li et al. (71) , in which SMAD3 binds, through the MH2 domain, to FOXL2 and not to the DNA.
The Cys 134 residue is located within the C-terminal region of the forkhead domain, required for both DNA binding (24) and interaction with SMAD3 (37). Considering this, it is conceivable that the C134W mutation may cause more stable interactions of FOXL2 with both FBE5 and SMAD3, resulting in the excessive expression of CYP19. A potential role for a GC mitogen, activin A, in the pathogenesis of GCTs is also plausible as C134W plus Myc-SMAD3 plasmids. Empty expression vectors were added as necessary to equalize the amount of plasmid transfected per well. After 4 hours, serum-free medium was replaced, and cells were cultured in the presence or absence of 100 ng/mL activin A for 24 hours followed by the collection of cell lysates. Protein lysates were immunoprecipitated with each probe precoupled to streptavidin-conjugated agarose beads, and FOXL2 protein was detected with an anti-Flag antibody. (c) Relative signal intensities of FOXL2 protein coprecipitated with streptavidin-conjugated agarose beads were measured. Representative results from triplicate experiments are presented. Data are shown as mean 6 SEM. Different letters denote significant difference among experimental conditions (P , 0.05). IB, immunoblotting; IP, immunoprecipitation; wt, wild-type.
activation of SMAD3 has been implicated in the pathogenesis of GCTs (42) .
CYP19 expression is a hallmark of aGCT, and serum E 2 levels are elevated in aGCT patients. There is not always a correlation between E 2 levels and the progression or recurrence of aGCTs (72, 73) , which may relate to a lack of theca cells in the tumor stroma of certain aGCTs (74) . In these patients, it is possible that, E 2 levels are normal yet CYP19 mRNA or protein levels are elevated. Additionally, serum inhibin B levels are markedly raised in women with aGCT (72, 75) . However, neither FOXL2 wt nor FOXL2 C134W regulated INHBB mRNA when cells were treated with or without activin A, or in the presence or absence of SMAD3 overexpression [ Fig. 1(b) and Fig. 2(b) ]. Nevertheless, our findings in the HGrC1 cells do not exclude the possibility that FOXL2 C134W is linked to the elevated level of inhibin B in vivo in aGCT patients.
Blount et al. (37) uncovered a synergistic effect of FOXL2 and SMAD3 in enhancing activin A stimulation of follistatin expression in the pituitary. We later reported that downregulation of endogenous FOXL2 in rat primary GCs resulted in increased follistatin mRNA expression, suggesting that, in contrast to the report in pituitary cells, FOXL2 is inhibitory in follistatin expression in the ovary (41) . Also, we showed that FOXL2 inhibits GDF9-induced follistatin transcription whereas FOXL2
C134W is more potent than FOXL2 wt in the inhibition in rat primary GCs. In the presence of SMAD3 overexpression, their inhibitory activities were more prominent (41 Collective data in the current study support that FOXL2 C134W and SMAD3 synergistically stimulate CYP19 transcription by binding to FBE5 in CYP19 promoter more strongly than FOXL2 wt and SMAD3.
